Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial
These findings suggest that intraperitoneal RNK001-based immunotherapy can be safely administered to recurrent EOC patients without inducing severe toxicity, while clinical and biochemical responses warrant further development.
Authors
- Janneke S. Hoogstad‐van Evert (ORCID: https://orcid.org/0000-0001-9838-0977)
- Anniek B. van der Waart (ORCID: https://orcid.org/0000-0001-5986-3060)
- Anna L. de Goede (ORCID: https://orcid.org/0000-0002-7176-6156)
- Nicolaas PM Schaap (ORCID: https://orcid.org/0000-0001-7696-4752)
- Vanessa Rodríguez‐Fanjul (ORCID: https://orcid.org/0000-0002-3386-5874)
- Joop H. Jansen (ORCID: https://orcid.org/0000-0001-9459-568X)
- Hanny Fredrix
- Harry Dolstra (ORCID: https://orcid.org/0000-0002-3998-687X)
- Bert A. van der Reijden (ORCID: https://orcid.org/0000-0001-7804-8643)
- Nelleke Ottevanger
- Lynn Bosmans
- Ruud L.M. Bekkers (ORCID: https://orcid.org/0000-0002-4577-8495)
- Petra L.M. Zusterzeel (ORCID: https://orcid.org/0000-0001-9547-6367)
- Willemijn Hobo (ORCID: https://orcid.org/0000-0002-8206-8185)
- Paul K.J.D. de Jonge (ORCID: https://orcid.org/0000-0002-1228-5002)
- Ellen Spijkers
- Merlize Djojoatmo
- Maud Wuts
- Lisanne M. A. Janssen
- Arnold van der Meer
Institutions
- Radboud University Nijmegen (NL)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- Radboud Institute for Molecular Life Sciences (NL)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1016/j.ygyno.2025.11.006
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Radboud Universitair Medisch Centrum